MédiMabs is pleased to announce you that we have set an official agreement with the CCAB for the commercialization of their research reagents under the brand MédiMabs – CCAB series. We are starting with 19 new antibodies against various cell surface targets + an antibody panel against 6 different FGFR isoforms. All of these high quality antibodies were developed by CCAB on their phage display platform. You can read the full press release on CCAB website.